<article id="dosing_BRVO" class="slide dosing" data-ag-name="Dosing BRVO">
  <div class="tab-title">BRVO</div>
  <h2 class="slide-title">TREAT-AND-EXTEND DOSING<sup class="footnote-link">1</sup></h2>
    <div class="body-content">
      <div class="text">
    <p>The recommended dose for EYLEA<sup class="reg">&reg;</sup> is 2 mg (0.05 mL or 50 µL) administered by intravitreal injection:</p>
    <ul>
      <li><strong>Monthly</strong> (interval between doses should not be shorter than one month)<span class="asterisk">*</span></li>
      <li><strong>Treatment interval may be extended up to 3 months</strong> based on visual and anatomic outcomes<sup class="cross">†</sup></li>
    </ul>
      </div>
    <img src="content_EN/img/badge.png" class="badge" />
    </div>
  </div>
  <div class="chart-img"><img src="content_EN/img/charts_dosing-brvo.png" /></div>
  <div class="keys">
    <div class="chart-key">* Clinical trial experience of a monthly dosing regimen of 2 mg aflibercept beyond 6 months in the BRVO indication is limited.</div>
    <div class="chart-key">† Prescribers should periodically assess (every 1 to 2 months) the need for continued therapy.</div>
    <div class="chart-key">‡ For illustrative purposes only. Individual patient needs may vary.</div>
  </div>
</article>